Molecular responses of vascular smooth muscle cells and phagocytes to curcumin-eluting bioresorbable stent materials

被引:39
作者
Nguyen, KT [1 ]
Shaikh, N [1 ]
Shukla, KP [1 ]
Su, SH [1 ]
Eberhart, RC [1 ]
Tang, LP [1 ]
机构
[1] Univ Texas, Dept Biomed Engn, Arlington, TX 76019 USA
关键词
polylactic acid; inflammation; drug delivery; cell proliferation; gene expression; restenosis; smooth muscle cells; phagocytes;
D O I
10.1016/j.biomaterials.2003.12.033
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A major complication of coronary stenting is restenosis, often accompanied by inflammatory reactions and smooth muscle cell proliferation. Curcumin has been shown to possess anti-inflammatory and anti-proliferative properties, thus we hypothesize that locally released curcumin by coronary stent would diminish in-stent restenosis. As a first test of this hypothesis, curcumin-eluting PLLA films (C-PLLA) were produced and the anti-inflammatory and anti-proliferative properties were then tested using peritoneal phagocytes and human coronary artery smooth muscle cell (hCASMCs) culture systems. We find that the addition of curcumin reduced phagocyte accumulation and activation on C-PLLA films. On the other hand, C-PLLA significantly reduced the proliferation, but not the adhesion, of hCASMCs. The molecular responses of hCASMCs to C-PLLA were further assessed by cDNA microarray analysis. Curcumin up-regulated genes related to apoptosis and enhanced the expression of anti-proliferative and anti-inflammatory factors, and of antioxidants. Equally important, C-PLLA inhibited the cell cycle progression of adherent hCASMCs. The results suggest that curcumin regulates gene expression and cell function through the protein kinase (PK) and mitogen-activated protein kinase (MAPK) pathways. These results support the use of curcumin to inhibit in-stent restenosis. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5333 / 5346
页数:14
相关论文
共 60 条
[1]   Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages [J].
Abe, Y ;
Hashimoto, S ;
Horie, T .
PHARMACOLOGICAL RESEARCH, 1999, 39 (01) :41-47
[2]  
AMMON HPT, 1993, J ETHNOPHARMACOL, V38, P113, DOI 10.1016/0378-8741(93)90005-P
[3]   PHARMACOLOGY OF CURCUMA-LONGA [J].
AMMON, HPT ;
WAHL, MA .
PLANTA MEDICA, 1991, 57 (01) :1-7
[4]  
[Anonymous], 1986, Laboratory manual of neutrophil Function
[5]   Curcumin is an in vivo inhibitor of angiogenesis [J].
Arbiser, JL ;
Klauber, N ;
Rohan, R ;
van Leeuwen, R ;
Huang, MT ;
Fisher, C ;
Flynn, E ;
Byers, HR .
MOLECULAR MEDICINE, 1998, 4 (06) :376-383
[6]   BIOCOMPATIBILITY OF 6 ELASTOMERS INVITRO [J].
BAKKER, D ;
VANBLITTERSWIJK, CA ;
DAEMS, WT ;
GROTE, JJ .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1988, 22 (05) :423-439
[7]  
Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772
[8]   CURCUMIN, AN ANTITUMOR PROMOTER AND ANTIINFLAMMATORY AGENT, INHIBITS INDUCTION OF NITRIC-OXIDE SYNTHASE IN ACTIVATED MACROPHAGES [J].
BROUET, I ;
OHSHIMA, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 206 (02) :533-540
[9]   Exploring the new world of the genome with DNA microarrays [J].
Brown, PO ;
Botstein, D .
NATURE GENETICS, 1999, 21 (Suppl 1) :33-37
[10]   INHIBITION OF TUMOR-NECROSIS-FACTOR BY CURCUMIN, A PHYTOCHEMICAL [J].
CHAN, MMY .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (11) :1551-1556